ArticleFrontiers in nutrition2025
Structural and functional characterization of gut microbiota in dyslipidemic patients from high-altitude Tibetan pastoral areas.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Approximately 49.3% of individuals living at high altitudes suffer from dyslipidemia. Emerging evidence indicates that gut microbiota can regulate lipid metabolism and cholesterol homeostasis, but the composition and function of gut microbiota in dyslipidemic patients from Tibetan pastoral regions remain unclear. Methods: To address this, we enrolled a cohort consisting of 22 dyslipidemic patients and 33 healthy controls (HCs) from the Gannan Tibetan pastoral region (average altitude: 3,600 m). Phenotypic data, blood, and fecal samples were collected from all the participants for a metagenome-wide association study based on shotgun metagenomic sequencing. Results: Compared with HCs, dyslipidemic patients showed a significant reduction in gut microbial diversity. Specifically, the abundance of beneficial species-including Discussion: These findings clarify the alterations in gut microbiota composition and function in plateau-dwelling dyslipidemic populations and their associations with blood lipid levels, suggesting potential microbial biomarkers for hyperlipidemia in plateau environments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.